CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.5500
+0.0200 (+1.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.5300
Open1.5300
Bid1.3500 x 800
Ask2.1300 x 1400
Day's Range1.4400 - 1.5670
52 Week Range0.6000 - 3.3300
Volume189,153
Avg. Volume608,777
Market Cap51.384M
Beta (3Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-0.9570
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents21 hours ago

    Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT

    Q1 2019 Curis Inc Earnings Call

  • Associated Press8 days ago

    Curis: 1Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted to extinguish debt, came to 19 cents per share. The drug developer posted revenue of $2.1 million in ...

  • Curis Reports First Quarter 2019 Financial Results
    PR Newswire8 days ago

    Curis Reports First Quarter 2019 Financial Results

    LEXINGTON, Mass., May 14, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2019.

  • PR Newswire15 days ago

    Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

    LEXINGTON, Mass., May 7, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial results on Tuesday, May 14, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • PR Newswire16 days ago

    Curis Completes Mesothelioma Enrollment in CA-170 Study

    LEXINGTON, Mass., May 6, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target enrollment of mesothelioma patients. Today's announcement is a direct result of those efforts," said James Dentzer, President & CEO of Curis. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression.

  • Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop
    Simply Wall St.26 days ago

    Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop

    It is doubtless a positive to see that the Curis, Inc. (NASDAQ:CRIS) share price has gained some 40% in the last three months. But spare a thought for the long term holders, who have held the stock as it bled value over the la...

  • Curis Regains Compliance with Nasdaq Continued Listing Requirements
    PR Newswirelast month

    Curis Regains Compliance with Nasdaq Continued Listing Requirements

    LEXINGTON, Mass., April 10, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities ("MVLS") for continued listing on the Nasdaq Global Market. On December 27, 2018, the Company had received a letter from Nasdaq notifying it that it was not in compliance with the MVLS requirement set forth in Listing Rule 5450(b)(2)(A).

  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire2 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., April 5, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019 (the "Q2 2019 Inducement Grant").

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT

    Q4 2018 Curis Inc Earnings Call

  • Associated Press2 months ago

    Curis: 4Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 18 cents per share. The drug developer posted revenue of $2.8 million in the period. For the year, the company reported that its loss narrowed ...

  • Curis Reports Fourth Quarter and Year-End 2018 Financial Results
    PR Newswire2 months ago

    Curis Reports Fourth Quarter and Year-End 2018 Financial Results

    LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2018. "2018 was a pivotal year for Curis as we transitioned from a company broadly engaged in discovery research and pipeline expansion into a company singularly focused on clinical execution," said James Dentzer, President and Chief Executive Officer of Curis. "As we move through 2019, we are focused on the development of first-in-class and best-in-class precision medicines that we hope will transform the lives of patients," he concluded.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • Benzinga2 months ago

    What's Driving The Rally In Microcap Biotech Curis?

    Thinly traded Curis, Inc. (NASDAQ: CRIS ) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it reached ...

  • Biotech News: Why Curis Stock Is Soaring Today
    InvestorPlace2 months ago

    Biotech News: Why Curis Stock Is Soaring Today

    A recent bit of biotech news involving Curis has CRIS stock flying high on Monday.Source: Shutterstock Curis (NASDAQ:CRIS) has announced that it has reached a deal with Oberland Capital Management in connection to Erivedge. This has it offering selling rights for a portion of royalty revenues to the group for $135.70 million.According to Curis, the deal with Oberland Capital Management has it receiving a starting payment of $65.00 million. It is then able to collect additional payments of up to $70.70 million from the company. However, Erivedge must reach certain milestones for CRIS to receive these payments.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe biotech news also includes Curis already making good use of the money from the deal. It notes that it used a portion of the cash from the deal to pay off some of its debts. It is also using the remaining $30 million from the upfront payment to funds its operations."We believe this structure provides Curis with substantial non-dilutive capital today, while retaining significant participation in the future upside potential of Erivedge," James Dentzer, President and CEO of Curis, said in a statement. "The proceeds of this transaction further strengthen our cash position as we fund our three lead therapeutic candidates to reach their near term development catalysts and beyond." * 7 Marijuana Stocks to Play the CBD Trend Erivedge is a drug from Curis that is used to treat patients suffering from Hedgehog signaling due to genetic mutations. The drug does this by targeting a protein called Smoothened.CRIS stock was up 31% as of Monday morning and is up 74% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Curis Stock Is Soaring Today appeared first on InvestorPlace.

  • MarketWatch2 months ago

    Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties

    Shares of Curis Inc. rocketed 93% in very active premarket trade Monday, after the biotechnology company said it reached an agreement to sell a portion of royalties of its Erivedge cancer treatment for up to $135.7 million to funds managed by Oberland Capital Management LLC. Volume swelled to 1.8 million shares ahead of the open, compared with the full-day average of about 174,000 shares. Under terms of the deal, Curis received $65 million upfront, and is entitled to receive up to an additional $70.7 million in milestone payments if future royalties exceed pre-determined thresholds. In comparison, the company reported a third-quarter net loss of $7.22 million and revenue of $2.85 million. "We believe this structure provides Curis with substantial non-dilutive capital today, while retaining significant participation in the future upside potential of Erivedge," Curis Chief Executive James Dentzer said. "The proceeds of this transaction further strengthen our cash position as we fund our three lead therapeutic candidates to reach their near term development catalysts and beyond." Thes tock has tumbled 60% over the past 12 months through Friday, while the iShares Biotechnology ETF has tacked on 2.7% and the S&P 500 has gained 8.2%.

  • PR Newswire2 months ago

    Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge. Under the terms of the agreement, Curis received $65.0 million in an upfront cash payment, plus Curis is entitled to receive up to an additional $70.7 million in milestone payments if future net royalties exceed pre-defined annual and cumulative thresholds.

  • PR Newswire2 months ago

    Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.

  • PR Newswire3 months ago

    Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

    LEXINGTON, Mass. , March 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • PR Newswire4 months ago

    Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

    LEXINGTON, Mass. , Feb. 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
    Zacks4 months ago

    Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • PR Newswire4 months ago

    First Mesothelioma Patient Dosed in CA-170 Study

    LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression. The company had previously announced its expectation to begin enrollment of mesothelioma patients in a dedicated cohort within the existing Phase 1 study.

  • First Eagle Investment Sells Stake in Curis Inc. at Steep Loss
    GuruFocus.com4 months ago

    First Eagle Investment Sells Stake in Curis Inc. at Steep Loss

    First Eagle Investment (Trades, Portfolio) Management axed 90.99% of its stake in Curis Inc. (CRIS) on Dec. 31 as the stock hovered near all-time low prices, the New York-based firm disclosed Wednesday. Warning! GuruFocus has detected 3 Warning Signs with CRIS.

  • Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
    Zacks4 months ago

    Is Curis (CRIS) Outperforming Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • Top 3 Healthcare Penny Stocks for 2018
    Investopedia4 months ago

    Top 3 Healthcare Penny Stocks for 2018

    These three healthcare penny stocks are poised for positive performance in the final quarter of 2018.